BSJ-5-63

Overview

BSJ-5-63 is a potent CDK12 , CDK7 , CDK9 PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12 , CDK7 , CDK9 , RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer . (Pink: CDK12 and CDK7 and CDK9 ligand ( HY-150948 ); Blue: VHL ligand ( HY-112078 ); Black: linker ( HY-W140827 )).

Application

Products | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Prostate Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-162706
• CAS No.: 2519823-37-9
• Molecular Formula: C52H74ClN9O6S2
• Molecular Weight: 1020.78
• Purity: 99.97%
• Storage: Store at room temperature 3 years. In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 5 mg/mL (4.90 mM); Clear solution
• Availability: In-stock

Source

Original product source